Research Topics
| T A PearsonSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Carotid endarterectomy and carotid artery stenting utilization trends over timeMatthew R Skerritt
Department of Community and Preventive Medicine, Rochester, NY, USA
BMC Neurol 12:17. 2012....
Who is maintaining weight in a middle-aged population in Sweden? A longitudinal analysis over 10 yearsAnne N Nafziger
Epidemiology and Public Health Sciences, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden
BMC Public Health 7:108. 2007..The aim of this study is to characterize who is not gaining weight during a 10 year period in Sweden...
Capacity for research in minority health: the need for infrastructure plus willT A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine, New York, USA
Am J Med Sci 322:243-7. 2001..These additional efforts at the community level should create a fertile environment to develop research and, ultimately, test strategies for reducing national disparities in cardiovascular health...- Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levelsThomas Pearson
University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Am J Cardiol 99:1706-1713. 2007..In conclusion, the lipid-modulating and anti-inflammatory effects of ezetimibe/simvastatin provide additional benefits not realized by statin monotherapy alone... - Heightened risk of cardiovascular disease in patients with rheumatoid arthritis, heightened risk of cardiovascular disease in patients with rheumatoid arthritis. IntroductionThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
Am J Med 121:S1-2. 2008 
Translation of evidence-based guidelines in preventive cardiology: the EUROACTION programThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, NY 14642, USA
Nat Clin Pract Cardiovasc Med 6:8-9. 2009..The EUROACTION program is an example of effectiveness research, which aims to develop and validate strategies to implement interventions previously shown to be efficacious...- The prevention of cardiovascular disease: have we really made progress?Thomas A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, New York, USA
Health Aff (Millwood) 26:49-60. 2007..Policy options that involve multiple preventive approaches offer the best opportunity to minimize the economic and social burdens of CVD... - Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Am J Cardiol 103:369-74. 2009..The effects of ezetimibe monotherapy are not well defined. The effects of ezetimibe on CRP were consistent across patient subgroups... - The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery diseaseThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester, Rochester, New York 14642, USA
Am J Cardiol 94:4F-8F. 2004..Risk reduction in this group, which contributes a significant portion of CAD cases, should be part of any program to reduce the population burden of CAD... - Education and income: double-edged swords in the epidemiologic transition of cardiovascular diseaseThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Ethn Dis 13:S158-63. 2003..The goal of improved education and eradication of poverty in Africa should not and need not carry the unhappy consequence of a cardiovascular disease epidemic... - Community participatory research with deaf sign language users to identify health inequitiesSteven Barnett
Department of Family Medicine, Rochester Prevention Research Center National Center for Deaf Health Research, University of Rochester Medical Center, Rochester, NY 14642, USA
Am J Public Health 101:2235-8. 2011..g., a low prevalence of current smokers) and 3 glaring health inequities: obesity, partner violence, and suicide. This collaborative work represents the first time a deaf community has used its own data to identify health priorities... - Translation of nutritional sciences into medical education: the Nutrition Academic Award ProgramT A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Am J Clin Nutr 74:164-70. 2001.... - Capacity for research in minority health: the need for infrastructure plus willT A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine, New York, USA
Am J Med Sci 322:243-52. 2001..These additional efforts at the community level should create a fertile environment to develop research and, ultimately, test strategies for reducing national disparities in cardiovascular health... - Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlledThomas Pearson
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Am J Geriatr Pharmacother 3:218-28. 2005.... - A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trialThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 644, Rochester, NY 14642, USA
Mayo Clin Proc 80:587-95. 2005..The addition of ezetimibe to statin therapy should be considered for patients not achieving their NCEP ATP III LDL-C goals while receiving statin therapy alone... - Lipoprotein(a): implications for clinical practiceRobert C Block
Department of Community and Preventive Medicine, University of Rochester Medical Center, Rochester, NY 14627, USA
Curr Atheroscler Rep 7:327-9. 2005 - Lateral automobile impacts and the risk of traumatic brain injuryJeffrey J Bazarian
Department of Emergency Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Ann Emerg Med 44:142-52. 2004..We determine the relative risk and severity of traumatic brain injury among occupants of lateral impacts compared with occupants of nonlateral impacts... - Comprehensive endovascular therapy for femoropopliteal arterial atherosclerotic occlusive diseaseMark G Davies
Center for Vascular Disease, Division of Vascular Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA
J Am Coll Surg 201:275-96. 2005 - Combination niacin and statin therapy in primary and secondary prevention of cardiovascular diseaseDeborah R Levy
University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Clin Cardiol 28:317-20. 2005..2 mmol/I (< 200 mg/dl). Combination therapy offers a means to get more people to goal. This paper reviews the impact of lipid-modifying combination therapy with niacin plus a statin on lipid profile outcomes... - Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness tThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA
Mayo Clin Proc 81:1177-85. 2006..CONCLUSION: Ezetimibe added to statin therapy is effective and well tolerated for improving the lipid profile and LDL-C goal attainment of patients regardless of race or ethnicity... - Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trialRonald G Schwartz
Cardiology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
J Am Coll Cardiol 42:600-10. 2003.... - Deaf sign language users, health inequities, and public health: opportunity for social justiceSteven Barnett
Family Medicine Research Programs, 1381 South Ave, Rochester, NY 14620 E mail Dr Barnett is also affiliated with the Rochester Prevention Research Center, National Center for Deaf Health Research the University of Rochester Department of Family Medicine and the University of Rochester Department of Community and Preventive Medicine, Rochester, New York
Prev Chronic Dis 8:A45. 2011..We describe 4 issues that underlie health inequities experienced by deaf sign language users and propose 6 public health approaches to address these health and health care inequities to promote health and prevent chronic diseases... - Integration of the Case-Based Series in Population-Oriented Prevention into a problem-based medical curriculumThomas A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, New York 14642, USA
Am J Prev Med 24:102-7. 2003..Issues of implementation and evaluation of the C-POP curriculum are discussed... - Breast cancer risk 55+ years after irradiation for an enlarged thymus and its implications for early childhood medical irradiation todayM Jacob Adams
University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine, 601 Elmwood Avenue, Box 644, Rochester, New York, USA
Cancer Epidemiol Biomarkers Prev 19:48-58. 2010.... - Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescentsMarc B Lande
Department of Pediatrics, University of Rochester Medical Center, 601 Elmwood Ave, Box 777, Rochester, NY 14642, USA
Pediatrics 122:1252-7. 2008..The objective of this study was to determine, with a nationally representative sample of children, whether the relationship between elevated blood pressure and C-reactive protein levels may be evident before adulthood... - Training medical students in community health: a novel required fourth-year clerkship at the University of RochesterScott McIntosh
Department of Community and Preventive Medicine, University of Rochester, Rochester, NY 14627 8969, USA
Acad Med 83:357-64. 2008..Evaluation efforts to date indicate that the clerkship has been received favorably by both faculty and students... - Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" CommentaryDeborah R Levy
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, New York, USA
J Gerontol A Biol Sci Med Sci 60:597-8; author reply 602. 2005 - Thyroid cancer risk 40+ years after irradiation for an enlarged thymus: an update of the Hempelmann cohortMICHAEL JACOB ADAMS
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Radiat Res 174:753-62. 2010..5 years of follow-up and is dose-dependent. Although the incidence appeared to decrease after 40 years, increased risk remains a lifelong concern in those exposed to lower doses of medical radiation during early childhood... - The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goalsT A Pearson
Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA
Arch Intern Med 160:459-67. 2000.... - New tools for coronary risk assessment: what are their advantages and limitations?Thomas A Pearson
Department of Community and Preventive Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Circulation 105:886-92. 2002..Systemic therapy for risk reduction in primary prevention may be preferable to local therapy (eg, angioplasty and bypass) and may more effectively prevent acute coronary events than these more invasive approaches... - Plasma sphingomyelin level as a risk factor for coronary artery diseaseX C Jiang
Department of Medicine, Columbia University, New York, NY 10032, USA
Arterioscler Thromb Vasc Biol 20:2614-8. 2000..Plasma SM levels could be a marker for atherogenic remnant lipoprotein accumulation and may predict lipoprotein susceptibility to arterial wall sphingomyelinase... - The undertreatment of LDL-cholesterol: addressing the challengeT A Pearson
Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
Int J Cardiol 74:S23-8. 2000..In conclusion, a large proportion of dyslipidemic patients who are being treated in primary care are not achieving NCEP target LDL-C levels... - Where do we go from here?Thomas A Pearson
Department of Community and Preventive Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
Am J Med 121:S32-4. 2008 - Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and womenChristine L Pelkman
Department of Exercise and Nutrition Sciences, The State University of New York at Buffalo, NY, USA
Am J Clin Nutr 79:204-12. 2004..There is merit in recommending a moderate-fat weight-loss diet... - Screening family members at high risk for coronary disease. Why isn't it done?J R Swanson
Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14623, USA
Am J Prev Med 20:50-5. 2001..The American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT) study, a national survey conducted in 1996-1997, determined if physicians were screening first-degree relatives of patients with early CVD... - Fluorescence-based, nonradioactive method for efficient detection of the pentanucleotide repeat (TTTTA)(n) polymorphism in the apolipoprotein(a) geneJ Rubin
Department of Medicine, Columbia University, New York, NY 10032, USA
Clin Chem 47:1758-62. 2001..CONCLUSIONS: We developed a nonradioactive technique that separates the PNR polymorphism in the apo(a) gene and can be used in other studies involving closely sized polymorphisms... - Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology IILuther T Clark
State University of New York Downstate Medical Center, Brooklyn, NY, USA
J Gen Intern Med 21:320-6. 2006..Additional research is needed to elucidate reasons for this disparity and to evaluate strategies for improving goal achievement among AA patients receiving therapy for dyslipidemia... - Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial statesLars Berglund
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Am J Clin Nutr 86:1611-20. 2007..In subjects with a high prevalence of metabolic risk abnormalities, the preferred replacement for saturated fat is unresolved... - The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and CaucasiansJill Rubin
Departments of Medicine, Columbia University, New York, NY, United States
Atherosclerosis 201:138-47. 2008..023). In conclusion, allele and haplotype frequencies and the nature of the linkage disequilibrium differed between African Americans and Caucasians at three apo(a) gene polymorphisms... - Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysisDonald A Berry
University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
Am Heart J 145:1036-45. 2003..One of these studies included 2 doses of atorvastatin, and substantial additional information is available in the literature about the effect of atorvastatin on LDL-C level lowering... - Metabolic syndrome components in african-americans and European-american patients and its relation to coronary artery diseaseErdembileg Anuurad
Department of Medicine, University of California Davis, Davis, California, USA
Am J Cardiol 100:830-4. 2007..Although our findings may not be directly extrapolated to the population at large, they illustrate the importance of a high-risk metabolic environment as a cardiovascular risk factor... - American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and PreThomas A Pearson
Circulation 107:645-51. 2003 - Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart AssociationThomas A Pearson
Circulation 107:499-511. 2003 - Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsMichael H Davidson
Radiant Development, Chicago, Illinois, USA
Am J Cardiol 96:556-63. 2005..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals... - AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association ScienThomas A Pearson
Circulation 106:388-91. 2002 - Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart diseaseSoma S Nag
Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania, USA
Am J Cardiol 95:862-4. 2005..The overall lipid-lowering therapy treatment rate was 38% and the estimated lipid treatment gap (percent needing treatment who were not receiving it) was 62%... - Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterolErdembileg Anuurad
Department of Medicine, University of California, Davis, CA, USA
J Lipid Res 47:2475-81. 2006.... - Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsDeepak L Bhatt
Cleveland Clinic, Cleveland, USA
N Engl J Med 354:1706-17. 2006..Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)... - CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overviewThomas A Pearson
Circulation 110:e543-4. 2004 - CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion groupStephen P Fortmann
Circulation 110:e554-9. 2004..Although considerable work has been published since this review was completed, the perspectives and issues presented are still useful in evaluating the use of inflammation markers for risk stratisfication and prevention... - Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialDeepak L Bhatt
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Am Coll Cardiol 49:1982-8. 2007..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)... - Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicityGuijing Lu
Department of Medicine, University of California Davis, USA, and Department of Medicine, Xiangya Hospital of Xiangya Medical School, Central South University, Changsha, P R China
Transl Res 149:317-23. 2007..05). The results indicate that, across gender and ethnicity, low adiponectin levels may be an independent risk factor for CAD... - Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke ForumSidney C Smith
Center for Cardiovascular Science and Medicine, University of North Carolina School of Medicine, Chapel Hill 27599-7075, USA
Circulation 109:3112-21. 2004 - A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialDeepak L Bhatt
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Am Heart J 150:401. 2005..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis... - B vitamins and restenosis after coronary angioplastyDoru V Chirieac
N Engl J Med 346:1093-5. 2002 - Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiologyBarbara V Howard
Circulation 105:e132-7. 2002 - Task Force on Strategic Research Direction: Population/Outcomes/Epidemiology/Social Science Subgroup key science topics reportLori Mosca
Circulation 106:e167-72. 2002 - Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practicesMary N Walsh
Northside Cardiology, Indianapolis, Ind, USA
Am J Manag Care 8:937-46. 2002..To observe the experience of 9 practice sites in implementing provider-defined disease management programs for coronary heart disease patients... - An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialThomas H Wang
Cleveland Clinic, Cleveland, OH, USA
Eur Heart J 28:2200-7. 2007..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population... - ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset StudyErdembileg Anuurad
Department of Medicine, University of California, Davis, CA, USA
J Lipid Res 48:693-8. 2007..For large apo[a] sizes, apoE genotype contributed to the observed African American-Caucasian differences in allele-specific apo[a] levels... - Positioning technology to serve global heart health: the Fifth International Heart Health ConferenceThomas A Pearson
Eur J Cardiovasc Prev Rehabil 11:265-6. 2004 - High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-AmericansErdembileg Anuurad
Department of Medicine, University of California, Davis, Sacramento, California 95817, USA
J Clin Endocrinol Metab 93:1482-8. 2008..Lipoprotein(a) [Lp(a)] is an independent CVD risk factor where plasma levels are determined by the apolipoprotein(a) [apo(a)] gene, which contains inflammatory response elements... - Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-upDhananjay Vaidya
Johns Hopkins Medical Institutions, Baltimore, MD, USA
Am J Cardiol 100:1410-5. 2007..In conclusion, in families with a history of premature CAD, the excess risk observed cannot be attributed to traditional risk factors, suggesting a major role for as yet undetermined genetic and other susceptibility factors... - In the clinic. DyslipidemiaLaurie A Kopin
Ann Intern Med 147:ITC9-1-ITC9-16. 2007
Research Grants
- UNIVERSITY OF ROCHESTER NUTRITION ACADEMIC AWARD PROGRAMThomas Pearson; Fiscal Year: 2002..Dissemination of the curriculum and educational tools will be facilitated by programs in professional societies, collaboration with the food industry, and development of an easily accessible Website. ..
- CLINICAL RESEARCH CURRICULUMThomas Pearson; Fiscal Year: 2004..With completion of the RCRC, the trainee should have the theoretical, methodological, and practical knowledge and skills for a productive career in clinical research. ..
- Radiology Cancer Research Training CurriculumThomas Pearson; Fiscal Year: 2005..The curriculum will be seamlessly integrated within the confines of a radiology residency or fellowship program. ..
- RESEARCH TRAINING IN PREVENTIVE CARDIOLOGYThomas Pearson; Fiscal Year: 2006..abstract_text> ..